- Record: found
- Abstract: not found
- Article: not found
LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
T.B. Powles, V. Chistyakov, V. Beliakouski, A. Semenov, E. Everaert, Y. Baranau, V MORENO, B Perez Valderrama, Y Vano, G. Del Conte, Y Loriot, T.W. Kang, M. Tammaro, A O'Hagan, M Hosseini, S Triantos, H Chhabra, A. Santiago-Walker, A.O. Siefker-Radtke, V Moreno, A. O'HAGAN, M. HOSSEINI, TB Powles
2021
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.